The Therapeutic Aryl Hydrocarbon Receptor–Modulating Agent Tapinarof Regulates SEMA3A Expression in Human Keratinocytes through NRF2

This publication has 14 references indexed in Scilit:

• Tapinarof in the treatment of psoriasis: A review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor–modulating agent
  Journal of the American Academy of Dermatology, 2021
• Efficacy and patient-reported outcomes from a phase 2b, randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis
  Journal of the American Academy of Dermatology, 2021
• Calcium-Inducible MAPK/AP-1 Signaling Drives Semaphorin 3A Expression in Normal Human Epidermal Keratinocytes
  Journal of Investigative Dermatology, 2020
• Aryl Hydrocarbon Receptor in Atopic Dermatitis and Psoriasis
  International Journal of Molecular Sciences, 2019
• Antioxidative Phytochemicals Accelerate Epidermal Terminal Differentiation via the AHR-OVOL1 Pathway: Implications for Atopic Dermatitis
  Acta Dermato-Venereologica, 2018
• Tapinarof Is a Natural AhR Agonist that Resolves Skin Inflammation in Mice and Humans
  Journal of Investigative Dermatology, 2017
• Itch and nerve fibers with special reference to atopic dermatitis: Therapeutic implications
  The Journal of Dermatology, 2014
• Topically applied semaphorin 3A ointment inhibits scratching behavior and improves skin inflammation in NC/Nga mice with atopic dermatitis
  Journal of Dermatological Science, 2012
• Identification of Ketoconazole as an AhR-Nrf2 Activator in Cultured Human Keratinocytes: The Basis of Its Anti-Inflammatory Effect
  Journal of Investigative Dermatology, 2012
• Semaphorin3A Alleviates Skin Lesions and Scratching Behavior in NC/Nga Mice, an Atopic Dermatitis Model
  Journal of Investigative Dermatology, 2008